Phase I dose escalation study of docetaxel with a fixed dose of S-1 in combination chemotherapy for advanced gastric cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Yeul Hong | - |
dc.contributor.author | Seo, Hee Yeon | - |
dc.contributor.author | Jeen, Yoon Tae | - |
dc.contributor.author | Kim, Hoon-Kyo | - |
dc.contributor.author | Shim, Byoung Yong | - |
dc.contributor.author | Yang, Jinmo | - |
dc.date.accessioned | 2021-09-08T20:58:19Z | - |
dc.date.available | 2021-09-08T20:58:19Z | - |
dc.date.created | 2021-06-19 | - |
dc.date.issued | 2009-01 | - |
dc.identifier.issn | 0344-5704 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/120784 | - |
dc.description.abstract | Background The primary objectives of this study were to estimate the maximum-tolerated dose (MTD) of docetaxel in combination with a fixed dose of S-1 and to determine the recommended dose (RD). Patients and methods Patients with histologically proven gastric carcinoma with metastatic or locally advanced inoperable disease were eligible. Patients received intravenous docetaxel starting at 40 mg/m(2) (dose level 1), and stepwise dose increases to 50, 60, and 70 mg/m2 were planned for successive patient cohorts (dose levels 2, 3, and 4, respectively) over 1 h on day 1 and oral S-1 administered at a fixed dose of 40 mg/m(2) twice daily on days 1-14, both drugs every 21 days. Results A total of 13 patients were enrolled into this trial. All three patients at dose level 3 developed dose-limiting toxicities (DLT), and this level was declared to be the MTD. Hence, level 2 (docetaxel 50 mg/m(2)) was declared to be the RD for the next study. As 9 of the 13 enrolled patients responded to treatment, the overall objective response rate was 69.2% (95% CI, 44.1-94.3%). The median time to progression was 8.38 months (range 1.44-8.51) and the overall survival duration was 9.9 months (range 0.62-11.57). The most common grade 3/4 toxicity of docetaxel plus S-1 was neutropenia, which was tolerable and manageable. Conclusion This regimen showed encouraging activity and a manageable safety profile in advanced gastric carcinoma and could be used in further randomized studies. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | SPRINGER | - |
dc.subject | ORAL FLUOROPYRIMIDINE | - |
dc.subject | SOLID TUMORS | - |
dc.subject | THERAPY | - |
dc.subject | TRIAL | - |
dc.subject | 5-FLUOROURACIL | - |
dc.subject | CAPECITABINE | - |
dc.subject | TAXOTERE | - |
dc.title | Phase I dose escalation study of docetaxel with a fixed dose of S-1 in combination chemotherapy for advanced gastric cancer | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Yeul Hong | - |
dc.contributor.affiliatedAuthor | Jeen, Yoon Tae | - |
dc.identifier.doi | 10.1007/s00280-008-0734-6 | - |
dc.identifier.scopusid | 2-s2.0-57149129932 | - |
dc.identifier.wosid | 000261286800007 | - |
dc.identifier.bibliographicCitation | CANCER CHEMOTHERAPY AND PHARMACOLOGY, v.63, no.2, pp.253 - 260 | - |
dc.relation.isPartOf | CANCER CHEMOTHERAPY AND PHARMACOLOGY | - |
dc.citation.title | CANCER CHEMOTHERAPY AND PHARMACOLOGY | - |
dc.citation.volume | 63 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 253 | - |
dc.citation.endPage | 260 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | ORAL FLUOROPYRIMIDINE | - |
dc.subject.keywordPlus | SOLID TUMORS | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | TRIAL | - |
dc.subject.keywordPlus | 5-FLUOROURACIL | - |
dc.subject.keywordPlus | CAPECITABINE | - |
dc.subject.keywordPlus | TAXOTERE | - |
dc.subject.keywordAuthor | Gastric neoplasm | - |
dc.subject.keywordAuthor | Docetaxel | - |
dc.subject.keywordAuthor | S-1 | - |
dc.subject.keywordAuthor | Combination chemotherapy | - |
dc.subject.keywordAuthor | Phase I | - |
dc.subject.keywordAuthor | Clinical trial | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.